Cover Image
Market Research Report

Global Car T Cell Therapy Market Research Report Forecast to 2025

Published by Market Research Future Product code 913700
Published Content info 79 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Car T Cell Therapy Market Research Report Forecast to 2025
Published: September 30, 2019 Content info: 79 Pages
Description

CAR T Cell Therapy Market Research Report - Global Forecast till 2025

Global CAR T Cell Therapy Market: Information by Target Antigen (CD19, CD22 and others), Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma and others) and Region - Forecast till 2025

The Global CAR T Cell Therapy Market is anticipated to register a CAGR of 58.52% to attain USD 8716.06 Million by the year 2025. Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy that is used for cancer treatment. In this therapy, T cells from patient body are separated and introduced in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient's cancer cells. The rising incidence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, growing pharmaceutical industry, and growth in the number of cell therapy clinical studies are pushing the growth of the global CAR T cell therapy market. However, side-effects of CAR T-cell therapy and high cost of treatment are likely to hinder the market growth. Growing frequency of cancer across the world, technological progress for advanced & reliable treatment for cancer, and increase in the number of cell therapy clinical studies are pushing the growth of the global CAR T cell therapy market. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Moreover, the growing pharmaceutical industry is also expected to boost market growth. One of the main strategies followed by players operating in the global CAR T cell therapy market were innovation, product growth, and acquisitions & mergers. In April 2019, Autolus Therapeutics PLC was granted with an orphan drug designation, to autologous improved T-cells, inherently altered with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of severe lymphoblastic leukemia (ALL), by the US FDA.

Market Segmentation

Global CAR T Cell Therapy Market has been segmented by Target Antigen, by application, and by region. Based on target antigen the market has been split into CD19, CD22, and Others. Based on application, the global CAR T Cell Therapy Market has been divided into Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma and Others. On the basis of region, the global CAR T Cell Therapy Market, by Region has been segmented US, Europe, China and Rest of the World

Regional Analysis

Geographically the global CAR T cell therapy market is split in regions like US, Europe, China, and the RoW. the major share of the global CAR T cell therapy market is expected to be held by US. This is owed to the growing cases of cancer in the country. Europe showed a significant amount of development in the market due to rise in the incidences of hematologic cancer such as leukemia, lymphoma, and multiple myeloma. Europe held a market share of 9.15% in the global CAR T cell therapy market. China is projected to substantially increase in the global market due to the emerging healthcare infrastructure and rising disposable income. Also, the market in the Middle East & Africa is projected to show the least growth owing to limited healthcare access and affordability among the population.

Key Players

The proposed spectators in the global CAR T cell therapy market are Hospitals, Pharmaceutical companies, Biotechnology Companies, Research institutes, Contract Research Organizations, Academic institutes. The major companies functioning in the global CAR T cell therapy market are concentrating on firming their global ways by entering into untouched markets. Pfizer, Inc. (US), Kite Pharma (US), Cellectis (France), Autolus Therapeutics PLC (UK), uno Therapeutics (US), Sorrento Therapeutics (US), (US), Mustang Bio (US), Novartis AG (Switzerland), CARsgen Therapeutics (China), Legend Biotech and others are some of the prominent players in the global CAR T cell therapy market.

Table of Contents

Table of Contents

1 Executive Summary

  • 1.1 Market Attractiveness Analysis

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model

4 Market Dynamics

  • 4.1 Introduction
  • 4.2 Drivers
    • 4.2.1 Increasing Prevalence of Cancer Across the Globe
    • 4.2.2 Technological Advancements in the Treatment Therapies for Cancer
    • 4.2.3 Growing Pharmaceutical Industry
    • 4.2.4 Increase in the Number of Clinical Studies for Cell Therapy
    • 4.2.5 Driver Analysis

5 Industry Analysis-Porter's Five Forces Model

  • 5.1 Porter's Five Forces Model
    • 5.1.1 Threat of New Entrants
    • 5.1.2 Bargaining Power of Suppliers
    • 5.1.3 Bargaining Power of Buyers
    • 5.1.4 Threat of Substitutes
    • 5.1.5 Intensity of Rivalry
  • 5.2 PEST Analysis
  • 5.3 Clinical Trials Analysis

6 Global CAR T Cell Therapy Market, By Target Antigen

  • 6.1 Key findings
    • 6.1.1 CD19
    • 6.1.2 CD22
    • 6.1.3 Others

7 Global CAR T Cell Therapy Market, By Application

  • 7.1 Key findings
    • 7.1.1 Diffuse Large B-Cell Lymphoma
    • 7.1.2 Acute Lymphoblastic Leukemia
    • 7.1.3 Others

8 Global CAR T Cell Therapy Market, By Region

  • 8.1 Introduction
  • 8.2 US
  • 8.3 Europe
  • 8.4 China
  • 8.5 Rest of the World (ROW)

9 Competitive Landscape

  • 9.1 Overview
  • 9.2 Competitive Benchmarking
  • 9.3 Leading Player in terms of Number of Developments in CAR T Cell Therapy Market
  • 9.4 Key Development Analysis
    • 9.4.1 Product Launches
    • 9.4.2 Regulatory Approvals
    • 9.4.3 Mergers & Acquisitions
    • 9.4.4 Expansions
    • 9.4.5 Joint Ventures
    • 9.4.6 IND Clearances

10 Company Profile

  • 10.1 Novartis AG
    • 10.1.1 Company Overview
    • 10.1.2 Financial Overview
    • 10.1.3 Products/Services Offered
    • 10.1.4 Key Developments
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Strategies
  • 10.2 Pfizer, Inc.
    • 10.2.1 Company Overview
    • 10.2.2 Financial Overview
    • 10.2.3 Products/Services Offered
    • 10.2.4 Key Developments
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Strategies
  • 10.3 Kite Pharma
    • 10.3.1 Company Overview
    • 10.3.2 Financial Overview
    • 10.3.3 Products/Services Offered
    • 10.3.4 Key Developments
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Strategies
  • 10.4 Cellectis
    • 10.4.1 Company Overview
    • 10.4.2 Financial Overview
    • 10.4.3 Products/Services Offered
    • 10.4.4 Key Developments
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Strategies
  • 10.5 Autolus Therapeutics PLC
    • 10.5.1 Company Overview
    • 10.5.2 Financial Overview
    • 10.5.3 Products/Services Offered
    • 10.5.4 Key Developments
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Strategies
  • 10.6 CARsgen Therapeutics
    • 10.6.1 Company Overview
    • 10.6.2 Financial Overview
    • 10.6.3 Products/Services Offered
    • 10.6.4 Key Developments
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Strategies
  • 10.7 Juno Therapeutics
    • 10.7.1 Company Overview
    • 10.7.2 Financial Overview
    • 10.7.3 Products/Services Offered
    • 10.7.4 Key Developments
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Strategies
  • 10.8 Sorrento Therapeutics, Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Financial Overview
    • 10.8.3 Products Offering
    • 10.8.4 Key Developments
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Strategy
  • 10.9 Legend Biotech
    • 10.9.1 Company Overview
    • 10.9.2 Financial Overview
    • 10.9.3 Products/Services Offered
    • 10.9.4 Key Developments
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Strategies
  • 10.1 Mustang Bio
    • 10.10.1 Company Overview
    • 10.10.2 Financial Overview
    • 10.10.3 Products/Services Offered
    • 10.10.4 Key Developments
    • 10.10.5 SWOT Analysis
    • 10.10.6 Key Strategies

11 Appendix

  • 11.1 References
  • 11.2 Related Reports

List of Tables

  • TABLE 1 PRIMARY INTERVIEWS
  • TABLE 2 CLINICAL TRIALS OVERVIEW
  • TABLE 3 GLOBAL CAR T CELL THERAPY MARKET BY TARGET ANTIGEN, 2017-2025 (USD MILLION)
  • TABLE 4 GLOBAL CAR T CELL THERAPY MARKET FOR CD19, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 5 GLOBAL CAR T CELL THERAPY MARKET FOR CD22, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 6 GLOBAL CAR T CELL THERAPY MARKET BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 7 GLOBAL CAR T CELL THERAPY MARKET FOR DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 8 GLOBAL CAR T CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 9 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 10 US CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2017-2025 (USD MILLION)
  • TABLE 11 US CAR T CELL THERAPY MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 12 EUROPE CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2017-2025 (USD MILLION)
  • TABLE 13 EUROPE CAR T CELL THERAPY MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 14 CHINA CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2017-2025 (USD MILLION)
  • TABLE 15 CHINA CAR T CELL THERAPY MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 16 REST OF THE WORLD (ROW) CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2017-2025 (USD MILLION)
  • TABLE 17 REST OF THE WORLD (ROW) CAR T CELL THERAPY MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 18 TOP MANUFACTURERS IN THE CAR T CELL THERAPY MARKET
  • TABLE 19 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE CAR T CELL THERAPY MARKET
  • TABLE 20 PRODUCT LAUNCHES
  • TABLE 21 REGULATORY APPROVALS
  • TABLE 22 MERGERS & ACQUISITIONS
  • TABLE 23 EXPANSIONS
  • TABLE 24 JOINT VENTURES
  • TABLE 25 IND CLEARANCES

List of Figures

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL CAR T CELL THERAPY MARKET
  • FIGURE 3 GLOBAL CAR T CELL THERAPY MARKET SHARE, BY TARGET ANTIGEN, 2018 (%)
  • FIGURE 4 GLOBAL CAR T CELL THERAPY MARKET BY TARGET ANTIGEN, 2017-2025 (USD MILLION)
  • FIGURE 5 GLOBAL CAR T CELL THERAPY MARKET SHARE, BY APPLICATION, 2018 (%)
  • FIGURE 6 GLOBAL CAR T CELL THERAPY MARKET BY APPLICATION, 2017-2025 (USD MILLION)
  • FIGURE 7 GLOBAL CAR T CELL THERAPY MARKET: MARKET STRUCTURE
  • FIGURE 8 RESEARCH PROCESS
  • FIGURE 9 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 10 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CAR T-CELL THERAPY MARKET
  • FIGURE 11 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL CAR T CELL THERAPY MARKET
  • FIGURE 12 ONGOING CLINICAL TRIALS PHASES (% SHARE)
  • FIGURE 13 KEY COMPANIES AND NUMBER OF CLINICAL TRIALS
  • FIGURE 14 KEY COMPANIES' CLINICAL TRIALS, (% SHARE)
  • FIGURE 15 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2018 (% SHARE)
  • FIGURE 16 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN, 2018 & 2025
  • FIGURE 17 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION, 2018 (% SHARE)
  • FIGURE 18 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION, 2018 & 2025
  • FIGURE 19 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2018 & 2025 (USD MILLION)
  • FIGURE 20 GLOBAL CAR T CELL THERAPY MARKET, BY REGION, 2018 (% SHARE)
  • FIGURE 21 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 22 CAR T CELL THERAPY MARKET, COMPETITIVE LANDSCAPE (% SHARE)
Back to Top